Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$19.74
+5.6%
$20.03
$16.65
$31.26
$824.54M0.91827,318 shs748,242 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.70
-2.8%
$11.75
$6.16
$16.73
$814.50M1.9918,439 shs710,824 shs
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$3.13
$2.67
$0.95
$4.18
$805.76M1.0710.27 million shs8.36 million shs
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$5.84
-10.8%
$6.80
$5.60
$15.57
$192.45M0.66156,344 shs278,785 shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
+3.35%-3.11%-20.05%-3.31%-27.69%
CryoPort, Inc. stock logo
CYRX
CryoPort
-2.06%+5.97%+32.57%+99.75%+161.49%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-0.32%0.00%+0.48%+15.07%+179.46%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
+4.63%-9.15%-11.37%-4.38%-31.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$19.74
+5.6%
$20.03
$16.65
$31.26
$824.54M0.91827,318 shs748,242 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.70
-2.8%
$11.75
$6.16
$16.73
$814.50M1.9918,439 shs710,824 shs
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$3.13
$2.67
$0.95
$4.18
$805.76M1.0710.27 million shs8.36 million shs
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$5.84
-10.8%
$6.80
$5.60
$15.57
$192.45M0.66156,344 shs278,785 shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
+3.35%-3.11%-20.05%-3.31%-27.69%
CryoPort, Inc. stock logo
CYRX
CryoPort
-2.06%+5.97%+32.57%+99.75%+161.49%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-0.32%0.00%+0.48%+15.07%+179.46%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
+4.63%-9.15%-11.37%-4.38%-31.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1.88
Reduce$24.0020.64% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.89
Moderate Buy$15.31-2.19% Downside
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
2.00
Hold$5.5476.71% Upside
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
2.67
Moderate Buy$32.60458.70% Upside

Current Analyst Ratings Breakdown

Latest RNAC, AMPH, CYRX, and ESPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$15.00 ➝ $20.00
6/3/2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Lower Price TargetEqual Weight$23.00 ➝ $20.00
5/27/2026
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Reiterated RatingOutperform$38.00
5/26/2026
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Lower Price TargetBuy$42.00 ➝ $40.00
5/20/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetOverweight$15.00 ➝ $17.00
5/14/2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Reiterated RatingOverweightEqual Weight$30.00 ➝ $19.00
5/12/2026
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Lower Price TargetBuy$30.00 ➝ $25.00
5/11/2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Reiterated RatingNeutral$25.00 ➝ $21.00
5/8/2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Reiterated RatingBuyHold
5/6/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
UpgradeSell (D+)Hold (C-)
5/5/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$11.00 ➝ $12.00
(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$720.53M1.22$4.67 per share4.26$17.17 per share1.16
CryoPort, Inc. stock logo
CYRX
CryoPort
$182.94M4.31N/AN/A$9.19 per share1.70
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$403.14M2.00N/AN/A($1.26) per share-2.49
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$1.78M96.59N/AN/A($4.85) per share-1.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$98.09M$1.6612.026.793.5611.00%15.12%7.14%8/6/2026 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M$1.3511.60N/AN/A41.57%-7.92%-4.79%8/4/2026 (Estimated)
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$22.68M-$0.06N/A14.252.550.12%-0.14%0.12%8/4/2026 (Estimated)
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$130.30M-$5.90N/AN/AN/A-8,550.65%N/A-28.25%8/6/2026 (Estimated)

Latest RNAC, AMPH, CYRX, and ESPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2026Q1 2026
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$0.02-$0.10-$0.08-$0.10$84.52 million$80.10 million
5/7/2026Q1 2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$0.70$0.42-$0.28$0.14$173.46 million$171.17 million
5/4/2026Q1 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million
4/30/2026Q1 2026
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$0.84-$1.46-$0.62-$1.46$0.22 million$0.08 million
3/10/2026Q4 2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$0.23$0.22-$0.01$0.22$165.12 million$168.45 million
3/9/2026Q4 2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$0.82-$1.38-$0.56-$3.57$0.10 million$0.95 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/AN/AN/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.79
3.85
2.82
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.09
2.00
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/A
1.53
1.18
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/A
7.65
7.65

Institutional Ownership

CompanyInstitutional Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
65.09%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
47.39%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
86.95%

Insider Ownership

CompanyInsider Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
29.60%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
1.60%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
37.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1,97644.09 million31.04 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.40 million45.36 millionOptionable
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
200257.43 million253.31 millionOptionable
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
6429.38 million18.45 millionOptionable

Recent News About These Companies

Cartesian Therapeutics (RNAC) Gets a Buy from Wedbush

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amphastar Pharmaceuticals stock logo

Amphastar Pharmaceuticals NASDAQ:AMPH

$19.74 +1.04 (+5.56%)
Closing price 04:00 PM Eastern
Extended Trading
$19.86 +0.13 (+0.63%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$15.70 -0.46 (-2.85%)
Closing price 04:00 PM Eastern
Extended Trading
$15.68 -0.01 (-0.10%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Esperion Therapeutics stock logo

Esperion Therapeutics NASDAQ:ESPR

$3.13 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$3.13 0.00 (-0.03%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Cartesian Therapeutics stock logo

Cartesian Therapeutics NASDAQ:RNAC

$5.84 -0.71 (-10.84%)
Closing price 04:00 PM Eastern
Extended Trading
$5.84 0.00 (-0.09%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.